Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT00061945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy also work in different ways to kill cancer cells or stop them from growing. Giving alemtuzumab together with combination chemotherapy may be a better way to block cancer growth.
Study identification
- NCT ID
- NCT00061945
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 302 participants
Conditions and interventions
Conditions
- Acute Undifferentiated Leukemia
- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Childhood Acute Lymphoblastic Leukemia
- L1 Adult Acute Lymphoblastic Leukemia
- L1 Childhood Acute Lymphoblastic Leukemia
- L2 Adult Acute Lymphoblastic Leukemia
- L2 Childhood Acute Lymphoblastic Leukemia
- Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
- Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
- Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- T-cell Adult Acute Lymphoblastic Leukemia
- T-cell Childhood Acute Lymphoblastic Leukemia
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
- allopurinol Drug
- cyclophosphamide Drug
- daunorubicin hydrochloride Drug
- vincristine sulfate Drug
- dexamethasone Drug
- asparaginase Drug
- filgrastim Biological
- imatinib mesylate Drug
- methotrexate Drug
- cytarabine Drug
- trimethoprim-sulfamethoxazole Drug
- mercaptopurine Drug
- leucovorin calcium Drug
- alemtuzumab Biological
- acyclovir Drug
- laboratory biomarker analysis Other
- pharmacological study Other
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2003 (Type not available)
- Primary completion
- Dec 2007 (Actual)
- Completion
- Oct 2012 (Actual)
- Last update posted
- May 3, 2022
2003 – 2012
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Leukemia Group B | Chicago | Illinois | 60606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00061945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00061945 live on ClinicalTrials.gov.